$RLMD
RELMADA THERAPEUTICS, INC. Stock $rlmd

$rlmd Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000121390024024013 Filed on March 19, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$9.683M	$12.08M	$48.89M
YoY Change	-21.23%	2.06%	2.02%
% of Gross Profit
Research & Development	$13.31M	$14.75M	$54.81M
YoY Change	-16.11%	-45.1%	-51.64%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$22.99M	$26.83M	$103.7M
YoY Change	-18.35%	-30.68%	-35.69%
Operating Profit	-$22.99M		-$103.7M
YoY Change	-18.35%		-35.69%
Interest Expense	$1.160M	$1.664M	$4.911M
YoY Change	-36.7%	119.53%	-328.79%
% of Operating Profit
Other Income/Expense, Net	$1.160M	$0.00	$0.00
YoY Change	-36.7%		-100.0%
Pretax Income	-$21.83M	-$25.17M	-$98.79M
YoY Change	-17.07%	-33.68%	-37.09%
Income Tax
% Of Pretax Income
Net Earnings	-$21.83M	-$25.17M	-$98.79M
YoY Change	-17.07%	-33.68%	-37.09%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.72		-$3.28
Diluted Earnings Per Share	-$0.72	-$0.84	-$3.28
COMMON SHARES
Basic Shares Outstanding	30.17M shares	30.10M shares	30.10M shares
Diluted Shares Outstanding	30.13M shares		30.10M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$83.61M	$96.32M	$96.32M
YoY Change	-36.87%	-35.06%	-35.06%
Cash & Equivalents	$1.335M	$4.092M	$4.092M
Short-Term Investments	$82.28M	$92.23M	$92.23M
Other Short-Term Assets	$752.3K	$1.185M	$1.185M
YoY Change	-75.65%	-70.63%	-70.63%
Inventory
Prepaid Expenses	$752.3K	$1.185M
Receivables
Other Receivables
Total Short-Term Assets	$84.37M	$97.51M	$97.51M
YoY Change	-37.75%	-36.21%	-36.21%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$43.13K	$43.13K	$43.13K
YoY Change	23.66%	23.67%	23.65%
Total Long-Term Assets	$43.13K	$43.12K	$43.12K
YoY Change	23.66%	23.64%	23.62%
TOTAL ASSETS
Total Short-Term Assets	$84.37M	$97.51M	$97.51M
Total Long-Term Assets	$43.13K	$43.12K	$43.12K
Total Assets	$84.41M	$97.55M	$97.55M
YoY Change	-37.74%	-36.2%	-36.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.189M	$3.506M	$3.506M
YoY Change	17.35%	-33.37%	-33.37%
Accrued Expenses	$7.173M	$8.689M	$8.689M
YoY Change	26.39%	20.56%	20.56%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$12.36M	$12.19M	$12.19M
YoY Change	22.43%	-2.2%	-2.2%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.36M	$12.19M	$12.19M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$12.36M	$12.19M	$12.19M
YoY Change	22.43%	-2.2%	-2.2%
SHAREHOLDERS EQUITY
Retained Earnings	-$582.7M	-$560.9M
YoY Change	19.31%	21.38%
Common Stock	$30.17K	$30.10K
YoY Change	0.25%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$72.05M	$85.36M	$85.36M
YoY Change
Total Liabilities & Shareholders Equity	$84.41M	$97.55M	$97.55M
YoY Change	-37.74%	-36.2%	-36.2%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$21.83M	-$25.17M	-$98.79M
YoY Change	-17.07%	-33.68%	-37.09%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$13.04M	-$10.25M	-$51.66M
YoY Change	-21.01%	-71.44%	-50.23%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$10.06M	$7.741M	$50.45M
YoY Change	-74.86%	-567.62%	155.67%
Cash From Investing Activities	$10.06M	$7.741M	$50.45M
YoY Change	-74.86%	-567.62%	155.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$221.7K	-98.46K	-98.46K
YoY Change		-124.02%	-100.22%
NET CHANGE
Cash From Operating Activities	-$13.04M	-10.25M	-51.66M
Cash From Investing Activities	$10.06M	7.741M	50.45M
Cash From Financing Activities	$221.7K	-98.46K	-98.46K
Net Change In Cash	-$2.757M	-2.607M	-1.304M
YoY Change	-111.73%	-92.98%	-96.66%
FREE CASH FLOW
Cash From Operating Activities	-$13.04M	-$10.25M	-$51.66M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.28
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022	rlmd	Aggregate Intrinsic Value Outstanding And Expected To Vest Granted1 AggregateIntrinsicValueOutstandingAndExpectedToVestGranted1		usd
CY2022	rlmd	Share Based Compensation Arrangements By Share Based Payment Award Options Exercised In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice
CY2022	rlmd	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractual Term1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1
CY2022	rlmd	Aggregate Intrinsic Value Outstanding And Expected To Vest Exercised1 AggregateIntrinsicValueOutstandingAndExpectedToVestExercised1		usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29628664	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30099203	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Entity File Number EntityFileNumber	000-55347
CY2023	dei	Entity Registrant Name EntityRegistrantName	Relmada Therapeutics, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-5401931
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	2222 Ponce de Leon Blvd
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Floor 3
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Coral Gables
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33134
CY2023	dei	City Area Code CityAreaCode	(786)
CY2023	dei	Local Phone Number LocalPhoneNumber	629 1376
CY2023	dei	Security12b Title Security12bTitle	Common Stock ($.001 par value)
CY2023	dei	Trading Symbol TradingSymbol	RLMD
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	72952616	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30174202	shares
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023	dei	Auditor Name AuditorName	Marcum llp
CY2023	dei	Auditor Location AuditorLocation	Houston, Texas
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4091568	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5395905	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	92232292	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	142926781	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	512432	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1185057	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4035186	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	97508917	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	152870304	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	43125	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	34875	usd
CY2023Q4	us-gaap	Assets Assets	97552042	usd
CY2022Q4	us-gaap	Assets Assets	152905179	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3506009	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5261936	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8688791	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7206941	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12194800	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12468877	usd
CY2023Q4	us-gaap	Liabilities Liabilities	12194800	usd
CY2022Q4	us-gaap	Liabilities Liabilities	12468877	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30099203	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30099203	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30099203	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30099203	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	30099	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	30099	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	646229824	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	602517138	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-560902681	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-462110935	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	85357242	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	140436302	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	97552042	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	152905179	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	113322999	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	54807348	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	48894945	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	47926077	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	103702293	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	161249076	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-103702293	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-161249076	usd
CY2022	rlmd	Gain On Settlement Of Fees GainOnSettlementOfFees	6351606	usd
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	5151704	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	2659424	usd
CY2023	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-4064391	usd
CY2022	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-585522	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	3823234	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-4220255	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4910547	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4205253	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-98791746	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-157043823	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.28
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.3
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30099203	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29628664	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	208264886	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	44194765	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	42728599	usd
CY2022	rlmd	Stock Issued During Period Value Share Exchange Prefunded Warrants Net Of Fees StockIssuedDuringPeriodValueShareExchangePrefundedWarrantsNetOfFees	-50000	usd
CY2022	rlmd	Adjustments To Additional Paid In Capital Warrants Exercised AdjustmentsToAdditionalPaidInCapitalWarrantsExercised	1264523	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	703720	usd
CY2022	rlmd	Stock Issued During Period Value Short Swing Profit Net StockIssuedDuringPeriodValueShortSwingProfitNet	373632	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-157043823	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	140436302	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	43811149	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-98463	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-98791746	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	85357242	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-98791746	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-157043823	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	43811149	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	44194765	usd
CY2022	rlmd	Gain On Settlement GainOnSettlement	6351606	usd
CY2023	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-4064391	usd
CY2022	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-585522	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	3823234	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-4220255	usd
CY2022	us-gaap	Increase Decrease In Leasing Receivables IncreaseDecreaseInLeasingReceivables	-86377	usd
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-512432	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	512432	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2841879	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-7259767	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1755927	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	421040	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1481850	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3338518	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-51659206	usd
CY2022	rlmd	Gain On Settlement Included In Other Incomeexpense GainOnSettlementIncludedInOtherIncomeexpense	6351606	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-103801617	usd
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	90463532	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	47293763	usd
CY2023	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	140916864	usd
CY2022	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	67027372	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	50453332	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	19733609	usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	98463	usd
CY2022	rlmd	Proceeds From Payment Of Fees For Warrants Issued For Common Stock ProceedsFromPaymentOfFeesForWarrantsIssuedForCommonStock	-50000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	42728599	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	703720	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1264523	usd
CY2022	rlmd	Proceed From Short Swing Profit Net ProceedFromShortSwingProfitNet	373632	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-98463	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	45020474	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1304337	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-39047534	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5395905	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44443439	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4091568	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5395905	usd
CY2022	rlmd	Forgiveness Of Accounts Payable Related To Gain ForgivenessOfAccountsPayableRelatedToGain	3212583	usd
CY2022	rlmd	Share Exchange For Prefunded Warrants ShareExchangeForPrefundedWarrants	1452	usd
CY2022	rlmd	Net Exercise Of Prefunded Warrants NetExerciseOfPrefundedWarrants	-1452	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-51659206	usd
CY2023Q4	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	560902681	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. The significant estimates are stock-based compensation expenses, and recorded amounts related to income taxes.</p>
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	4091568	usd
CY2023Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	92232292	usd
CY2023	rlmd	Gain On Settlements Policy Tect Block GainOnSettlementsPolicyTectBlock	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Gain on Settlement </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes a gain when cash (or other assets, such as claims to cash) has been received without the expectation of repayment. A gain is recorded when the assets are readily convertible to know amounts of cash or claims to cash. Gains are reported as part of other income (expense) on the consolidated statement of operations. The Company recorded a gain on settlement of $0 and $6,351,606 included in other income (expense) for the years ended December 31, 2023 and 2022, respectively.</p>
CY2023	rlmd	Gain On Settlement Included In Other Incomeexpense GainOnSettlementIncludedInOtherIncomeexpense	0	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	92232292	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	3823234	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-4220255	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19797558	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15150047	shares
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	365100	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	313200	usd
CY2023Q4	rlmd	Prepaid Research And Development PrepaidResearchAndDevelopment	695000	usd
CY2022Q4	rlmd	Prepaid Research And Development PrepaidResearchAndDevelopment	3619800	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	125000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	102200	usd
CY2023Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	1185100	usd
CY2022Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	4035200	usd
CY2022Q4	rlmd	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	5809800	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	174000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	116500	usd
CY2023Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	2632400	usd
CY2022Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	492100	usd
CY2023Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	372200	usd
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	529800	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	115500	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	258700	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	8688800	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	7206900	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1264523	usd
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	83698	shares
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	703720	usd
CY2022Q2	rlmd	Aggregate Of Offering Price AggregateOfOfferingPrice	100000000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	13052942	shares
CY2023	rlmd	Stock Options Exercisable Period StockOptionsExercisablePeriod	P10Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2023	rlmd	Number Of Share Approved For Issuance NumberOfShareApprovedForIssuance	4363250	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	5010000	shares
CY2021Q4	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P6Y3M
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	10000	shares
CY2023Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	23840	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount For Postvesting Restrictions ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions	0.042	pure
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.0444	pure
CY2023Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P6Y3M
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	60000	shares
CY2023Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	148420000000	usd
CY2023Q2	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P6Y3M
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	620000	shares
CY2023Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2023Q1	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P6Y3M
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	3.37
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	260000	shares
CY2022Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	5000000	usd
CY2022Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P6Y3M
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	260000	shares
CY2022Q2	rlmd	Class Of Warrants Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights1	25.52
CY2022Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	4600000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.95	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	15000	shares
CY2022Q1	rlmd	Class Of Warrants Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights1	25.76
CY2022Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	307845	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount For Postvesting Restrictions ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions	0.0255	pure
CY2022Q1	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P6Y3M
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.98	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	110000	shares
CY2022Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1600000	usd
CY2022Q1	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P6Y3M
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.98	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q1	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P5Y6M
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.96	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	10330622	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	22.52
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P9Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	46088534	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	3744432	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.4
CY2022	rlmd	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1	P9Y9M18D
CY2022	rlmd	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised	-83698	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1868750	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	12122606	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	18.19
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y6M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	417998	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	5700000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.61
CY2023	rlmd	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1	P9Y10M24D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	406414	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	17416192	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	12.99
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y3M18D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	11183370	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	7161748	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	20.25
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1015520	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1200000	usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	62386500	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y6M
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	41562000	usd
CY2022Q3	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	1452016	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount For Postvesting Restrictions ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions	0.0999	pure
CY2023	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	3200000	usd
CY2023	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	19000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	43811100	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	44194800	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	21016000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	24964000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	3771000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	13781000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2238000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	7902000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	49581000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	45666000	usd
CY2023	rlmd	Deferred Tax Assets Nonqualified Stock Options DeferredTaxAssetsNonqualifiedStockOptions	29305000	usd
CY2022	rlmd	Deferred Tax Assets Nonqualified Stock Options DeferredTaxAssetsNonqualifiedStockOptions	19803000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1616000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1546000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2599000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2732000	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	11000	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	2000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	110137000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	116396000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-6259000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	20201000	usd
CY2023	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	88611000	usd
CY2023Q4	rlmd	Taxable Income Percentage TaxableIncomePercentage	0.80	pure
CY2023Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	2237600	usd
CY2023	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	Accordingly, about $111,168,000 of the Company’s NOL carryforwards are limited.
CY2023Q4	rlmd	Available Of Operating Loss Carry Forwards AvailableOfOperatingLossCarryForwards	1109000	usd
CY2023Q4	rlmd	Changein Operating Loss Carryforwards ChangeinOperatingLossCarryforwards	740000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0656	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0946	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0534	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0053	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.017	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0164	pure
CY2023	rlmd	Effective Income Tax Rate Nol And Rd Adjustment EffectiveIncomeTaxRateNOLAndRDAdjustment	-0.1627	pure
CY2022	rlmd	Effective Income Tax Rate Nol And Rd Adjustment EffectiveIncomeTaxRateNOLAndRDAdjustment	0	pure
CY2023	rlmd	Effective Income Tax Rate Reconciliation Permanent Trueups EffectiveIncomeTaxRateReconciliationPermanentTrueups	-0.0089	pure
CY2022	rlmd	Effective Income Tax Rate Reconciliation Permanent Trueups EffectiveIncomeTaxRateReconciliationPermanentTrueups	0	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0002	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0022	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.0634	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1287	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023	rlmd	Royalty Payments RoyaltyPayments	0.02	pure
CY2023	rlmd	Royalties Received RoyaltiesReceived	0.20	pure
CY2023	rlmd	Net Sales NetSales	0.02	pure
CY2018Q1	rlmd	Non Refundable License Fee NonRefundableLicenseFee	180000	usd
CY2018Q1	rlmd	Licenses Fee LicensesFee	45000	usd
CY2018Q1	rlmd	Royalty Payments Percentage RoyaltyPaymentsPercentage	0.02	pure
CY2018Q1	rlmd	Tiered Payments TieredPayments	0.20	pure
CY2023	us-gaap	Taxes And Licenses TaxesAndLicenses	45000	usd
CY2021Q3	us-gaap	Entertainment License Agreement For Program Material Capitalized Cost EntertainmentLicenseAgreementForProgramMaterialCapitalizedCost	12700000	usd
CY2021Q3	us-gaap	Development In Process DevelopmentInProcess	160000000	usd
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	11000	usd
CY2021Q3	rlmd	Lease Period LeasePeriod	P5M
CY2022	us-gaap	Payments For Rent PaymentsForRent	9000	usd
CY2023	us-gaap	Payments For Rent PaymentsForRent	7000	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	14500	usd
CY2023Q4	us-gaap	Operating Lease Expense OperatingLeaseExpense	12000	usd
CY2022	rlmd	Rent Expense RentExpense	283600	usd
CY2023	rlmd	Rent Expense RentExpense	129600	usd
CY2022Q4	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	7529	usd
CY2023	us-gaap	Securities Purchased Under Agreements To Resell Increase SecuritiesPurchasedUnderAgreementsToResellIncrease	496914	usd
CY2022Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	52698	usd
CY2023Q4	us-gaap	Lessor Operating Lease Assumptions And Judgments Value Of Underlying Asset Amount LessorOperatingLeaseAssumptionsAndJudgmentsValueOfUnderlyingAssetAmount	493452	usd
CY2023	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	397049	usd
CY2023	us-gaap	Malpractice Loss Contingency Discount Rate MalpracticeLossContingencyDiscountRate	0.0838	pure
CY2023	us-gaap	Proceeds From Sale And Collection Of Lease Receivables ProceedsFromSaleAndCollectionOfLeaseReceivables	96403	usd
CY2023	us-gaap	Description Of Defined Contribution Pension And Other Postretirement Plans DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans	The Company matches 100% of the first 3% of employee contributions, plus 50% of employee contributions that exceed 3% but do not exceed 5%.
CY2023	rlmd	Employee Contribution Expense EmployeeContributionExpense	140982	usd
CY2022	rlmd	Employee Contribution Expense EmployeeContributionExpense	105216	usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	74999	shares
CY2023	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	246747	usd
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent		usd
CY2023	rlmd	Gain On Settlement Of Fees GainOnSettlementOfFees		usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.30
CY2022	rlmd	Stock Issued During Period Value Net Exercise Prefunded Warrants StockIssuedDuringPeriodValueNetExercisePrefundedWarrants		usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		usd
CY2023	rlmd	Proceeds From Payment Of Fees For Warrants Issued For Common Stock ProceedsFromPaymentOfFeesForWarrantsIssuedForCommonStock		usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2023	rlmd	Proceed From Short Swing Profit Net ProceedFromShortSwingProfitNet		usd
CY2023	rlmd	Forgiveness Of Accounts Payable Related To Gain ForgivenessOfAccountsPayableRelatedToGain		usd
CY2023	rlmd	Share Exchange For Prefunded Warrants ShareExchangeForPrefundedWarrants		usd
CY2023	rlmd	Net Exercise Of Prefunded Warrants NetExerciseOfPrefundedWarrants		usd
CY2023Q4	rlmd	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	5.394700	usd
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2022	rlmd	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Average Remaining Contractual Term1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm1
CY2022	rlmd	Aggregate Intrinsic Value Outstanding And Expected To Vest Forfeited1 AggregateIntrinsicValueOutstandingAndExpectedToVestForfeited1		usd
CY2023	rlmd	Aggregate Intrinsic Value Outstanding And Expected To Vest Granted1 AggregateIntrinsicValueOutstandingAndExpectedToVestGranted1		usd
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023	rlmd	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Average Remaining Contractual Term1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm1
CY2023	rlmd	Aggregate Intrinsic Value Outstanding And Expected To Vest Forfeited1 AggregateIntrinsicValueOutstandingAndExpectedToVestForfeited1		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001553643

Files In Submission

Name	View Source	Status
0001213900-24-024013-index-headers.html	Edgar Link	pending
0001213900-24-024013-index.html	Edgar Link	pending
0001213900-24-024013.txt	Edgar Link	pending
0001213900-24-024013-xbrl.zip	Edgar Link	pending
f10k2023ex23-1_relmada.htm	Edgar Link	pending
f10k2023ex31-1_relmada.htm	Edgar Link	pending
f10k2023ex31-2_relmada.htm	Edgar Link	pending
f10k2023ex32-1_relmada.htm	Edgar Link	pending
f10k2023ex32-2_relmada.htm	Edgar Link	pending
f10k2023_relmadatherap.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
f10k2023_relmadatherap_htm.xml	Edgar Link	completed
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rlmd-20231231.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
rlmd-20231231_cal.xml	Edgar Link	unprocessable
rlmd-20231231_def.xml	Edgar Link	unprocessable
rlmd-20231231_lab.xml	Edgar Link	unprocessable
rlmd-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RLMD
RELMADA THERAPEUTICS, INC. Stock $rlmd

2024 Q1 Form 10-K Financial Statement

#000121390024024013 Filed on March 19, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RLMD RELMADA THERAPEUTICS, INC. Stock $rlmd

2024 Q1 Form 10-K Financial Statement

#000121390024024013 Filed on March 19, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RLMD
RELMADA THERAPEUTICS, INC. Stock $rlmd